Lantheus is a cash-generative radiopharmaceutical leader entering a pivotal transition as Pylarify competition rises, TruVu and Neuraceq seek to reignite growth, and valuation upside depends on flawless execution.
Overview
Lantheus is a leading radiopharmaceutical company focused on diagnostic imaging and precision medicine across oncology, cardiology, and neurodegenerative disease. Its revenue is dominated by Pylarify, a prostate cancer PSMA PET imaging agent representing roughly 70% of sales, while Definity provides a durable cardiology franchise and Neuraceq adds Alzheimer’s imaging optionality. The company benefits from strong U.S. commercial infrastructure, clinical evidence, and a broad PET manufacturing network, but remains heavily exposed to Pylarify competition, reimbursement changes, pricing pressure, and execution risks during a strategic transition.